A 35-Day, Multi-Centre, Randomised, Parallel-Group, Double-Blind, Placebo-Controlled Proof of Concept Study to Investigate the Effects of GSK1521498 on Body Weight and Composition, Eating Behaviour and Related Brain Function, in Obese Subjects With Over-Eating Behaviours.
Phase of Trial: Phase II
Latest Information Update: 26 May 2014
At a glance
- Drugs GSK 1521498 (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 25 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 May 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 28 Jan 2011 Status changed from not yet recruiting to recruiting as reported by ClnicalTrials.gov.